小剂量胺碘达隆联合β受体阻滞剂治疗复发性阵发性房颤

目的：探讨小剂量胺碘达隆联合β受体阻滞剂治疗阵发性房颤的疗效和安全性。方法：将４４例复发性阵发性房颤（ＲＰＡＦ）随机分成单用胺碘达隆组（ＡＤ）２０例和胺碘达隆＋β受体阻滞剂组（ＡＤ＋βＢ）２４例，观察两组房颤发作控制效果及药物长期使用的副作用。结果：ＡＤ组和ＡＤ＋βＢ组追踪时间分别为［２４～４８（３１．０±９．６）］月及［１４～６０（３５．０±１７．９）］月，长期维持窦性心律，平均最小有效维持量分别为：（２３３．０±１０３．３）ｍｇ和（１５４．４±５２．５）ｍｇ／ｄ（Ｐ＜０．００５）。两组控制房颤复发的有效率分别为１１例（５５％）和２２例（９１．６％）（Ｐ＜０．０２５），两组均未见明显副作用。结论：胺碘达隆＋β受体阻滞剂联合治疗ＲＰＡＦ，不仅其疗效明显提高，且由于用量明显减少，故可减轻胺碘达隆长期应用的潜在副作用。

The Treatment of Recurrent Paroxysmal Atrial Fibrillation with a Small Dose of Schedule of Amiodatone and β-Blokers

Objective:To Study the efficacy and Safety of a small dosage schedule of aminodarone combined with β blockers for recurent paroxysmal atricl fibrillation(RPAF).Methods:24 patients with RPAF were randomly divided into two long-term therapy groups:administration of amiodarone only (20 cases) (GroupⅠ) and administration of amiodarone combined with β blockers in small doses(24 cases)(Group Ⅱ).The side effects of drug and the control of RPAF were observed in both groups.Results:The effects rate of RPAF control is found to be 91.67%(22/24)in Group Ⅰ and 55% (11/20) in Group Ⅱ.The average minimum effective mainranace dosage is 154.4±52.5 mg/d and 233±103.3 mg/d respectively.No side effects and episodes of AF occurred in both groups during the mean follow-up period of 35±17.9 months(from 14 to 60 months).Conclusion:It is suggested that the treatment of RPAF with a small dsage schedule of aminodarone and β blokers can not only improve the therapeutic effectiveness but also reduce the potential side effects from a long-term use of amiodarone,owing to a remarkable reduction in dose.